Market Overview

UPDATE: Goldman Sachs Initiates Genomic Health at Neutral on Limited Upside

Share:
Related GHDX
Genomic Health Cancer Tests Strong, Operating Expenses a Woe
Why Is Genomic Health (GHDX) Up 7.1% Since the Last Earnings Report?

Goldman Sachs initiated coverage on Genomic Health (NASDAQ: GHDX) with a Neutral rating and a $36 price target.

Goldman Sachs commented, "Our thesis is based on (1) growth potential from new product cycles offset by (2) underappreciated market development costs and (3) mounting competition and an uncertain regulatory environment. How we are different: Our proprietary analysis of GHDX's new products and the regulatory landscape suggests these new tests may improve on the standard of care but face material uncertainties that are not yet fully appreciated by the Street."

Genomic Health closed at $33.77 on Wednesday.

Latest Ratings for GHDX

DateFirmActionFromTo
Aug 2017Canaccord GenuityMaintainsBuy
May 2017Raymond JamesDowngradesOutperformMarket Perform
Jan 2017Deutsche BankInitiates Coverage OnHold

View More Analyst Ratings for GHDX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (GHDX)

View Comments and Join the Discussion!
Loading...
Loading...